AntoXa

Life-saving biodefense solutions

  • About Us
    • Management Team
  • Products
  • Investors
  • News
  • Contact
You are here: Home / News Releases / Study shows antibody’s efficacy against ricin

Study shows antibody’s efficacy against ricin

September 13, 2017 By antoxa

AntoXa is working with Defence Research & Development Canada (DRDC) to develop and produce a plant-made antibody, PhD9, to protect against ricin exposure, a program that has received more than $400,000 (CDN) from the Government of Canada since 2014.

Ricin is a naturally occurring protein from Ricinus communis. It is extremely toxic to humans when inhaled or injected and is considered a high bioterrorism risk for the public. Ricin is listed as a Category B threat agent by the U.S. Centers for Disease Control and Prevention due to its ease of production, worldwide availability, relative stability and extreme lethality.

There is currently no antidote against ricin poisoning. It acts very quickly and leaves a short window for administering therapeutic antibodies.

The PhD9 antibody drug candidate developed by DRDC and produced using AntoXa’s vivoXPRESS® system prevents ricin from penetrating cells. DRDC conducted in vitro and in vivo studies that found the plant-made version of the antibody showed therapeutic efficacy against ricin intoxication that was comparable to hD9 produced using mammalian cell technology. The findings were presented at the Antibody Engineering and Therapeutics Conference in December 2015.

“We’re very encouraged by the initial study results for the plant-produced anti-ricin antibody,” said Dr. Don Stewart, AntoXa President and CEO. “We believe that plants hold the key to cost-effective, large-scale production of antidotes for ricin and other potential bioterrorism threats.”

 

Filed Under: News Releases

Latest News

AntoXa awarded federal government contract for anti-nerve agent enzyme

March 20, 2019

GUELPH, Ontario, Canada, March 20, 2019 — AntoXa Corporation has been ...
Read more >

Ashley J. Meyers appointed President and COO of AntoXa Corporation

Ashley J. Meyers appointed President and COO of AntoXa Corporation

December 20, 2018

Guelph, Ont., Canada, Dec. 20, 2018 — AntoXa Corporation announced today ...
Read more >

Ron Hosking appointed to AntoXa Corporation Board of Directors

November 28, 2018

Guelph, Ont., Canada, Nov. 28, 2018 — Ron Hosking, CPA, CA, has been ...
Read more >

About Us

Plant-made biopharmaceuticals for a safer world. AntoXa Corporation is a Canadian biopharmaceutical company developing medical countermeasures to protect military and civilian personnel from biological and chemical agents that might be used in terrorist attacks, as well as outbreaks of naturally ...
Read more >

Global Demand for Biodefense Therapeutics

Governments are investing billions of dollars preparing for potential bioterrorism attacks and ...
Read more >

Subscribe to our Newsletter

vivoXPRESS® MANUFACTURING SYSTEM
The tobacco-plant-based vivoXPRESS® manufacturing platform offers several advantages over the mammalian and bacterial cell culture systems used to produce most recombinant protein pharmaceuticals. Here’s how it works.

BioPharming Info Centre

Biopharming, also known as plant molecular farming, refers to the use of genetically modified plants to produce a wide range of pharmaceuticals and industrial products. See our Biopharming Info Centre to Learn more about the science and history of using plants to produce complex therapeutic proteins.

Copyright © 2021 · AntoXa Corporation | Site by DigitalNomad.marketing and Curry Gunn & Associates